New Treatment of Advanced Ovarian Cancer: A Literature Review
سال انتشار: 1398
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 148
متن کامل این مقاله منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل مقاله (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
این مقاله در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_JOGCR-4-4_001
تاریخ نمایه سازی: 20 دی 1399
چکیده مقاله:
Epithelial ovarian cancer is one of the most common gynecological malignancies worldwide with an incidence of 225000 cases annually. For most patients, multimodality treatment including cytoreductive surgery and combination chemotherapy is an accepted standard of care. Despite the relatively favorable response to initial treatment, relapse free survival and overall survival are disappointing in patients with advanced ovarian cancer. Therefore, new treatment approaches have been proposed in recent years. The present review aims to describe the most relevant data published during the last four years on new approach to advanced ovarian cancer. Therefore, relevant studies were searched through Pubmed, Cochrane library and Scopus database published online until 2019. The most important changes studied in recent years have included the addition of new chemotherapy or targeted agent to first-line chemotherapy. Although combination of intravenous paclitaxel and carboplatin is currently accepted as the standard of care for treatment of advanced ovarian cancer, discussion around the intraperitoneal chemotherapy is still an important challenge. Additionally, much efforts have been dedicated to design an appropriate maintenance treatment as a goal of diminish the risk of recurrence. This review summarizes the results of most recent phase 3 trials surrounding optimal first-line chemotherapy, addition of a targeted agent including bevacizumab and maintenance treatment.
کلیدواژه ها:
نویسندگان
Shirin Haghighat
Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran